Ranbaxy Pharmaceuticals Inc had applied for marketing approval of a version of Purdue’s painkiller, Oxycodone.
Read more from the original source:
Ranbaxy’s US arm to face patent infringement suit
Tags: for-marketing, had-applied, Oxycodone, pharmaceuticals
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market. Â The company plans to leverage its core expertise in the prescription pain category by developing a range of products that address both the acute and chronic pain prescription segments as well as the …
Go here to read the rest:
Xanodyne Announces Renewed Focus on Pain Management Market
Tags: april, core-expertise, pharmaceuticals, today-announced
King Pharmaceuticals is working to develop Oxycodone tablets that are harder to crush or dissolve.
Read the original post:
Local Company Helps Combat Drug Abuse
Tags: a-tip-about, agency-criminal, connection-with, Oxycodone, pharmaceuticals
King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox® (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of …
See more here:
King Pharmaceuticals And Acura Pharmaceuticals Announce Plans To Submit An NDA For Acuro(R) Tablets Without Niacin
Tags: and-intravenous, companies, pharmaceuticals, potential-abuse, without-niacin
BRISTOL, TN and PALATINE, IL–(Marketwire – 05/03/10) – King Pharmaceuticals, Inc. (NYSE: KG – News ) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR – News ) today announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential …
Original post:
King Pharmaceuticals and Acura Pharmaceuticals Announce Plans to Submit an NDA for Acurox(R) Tablets Without Niacin
Tags: and-introduce, application, companies, pharmaceuticals, without-niacin